These results implied a mechanism of taxane-resistance associated with activation of the PI3K/mTOR pathway and provided a rationale for the evaluation of PI3K/mTOR inhibitors in combination with anti-mitotic drugs in order to improve cancer treatment outcomes. The gene discussed is PIK3CA; the disease is cancer.